Business Description
Vaxxinity Inc
NAICS : 541714
SIC : 2834
ISIN : US92244V1044
Share Class Description:
VAXX: Class ADescription
Vaxxinity Inc is a biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company's proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 1.13 | |||||
| Debt-to-EBITDA | -0.28 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -11.9 | |||||
| 3-Year EPS without NRI Growth Rate | -18.9 | |||||
| 3-Year FCF Growth Rate | -17.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 7.83 | |||||
| 9-Day RSI | 11.46 | |||||
| 14-Day RSI | 16.08 | |||||
| 6-1 Month Momentum % | -33.6 | |||||
| 12-1 Month Momentum % | -68.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | |||||
| Quick Ratio | 1.89 | |||||
| Cash Ratio | 1.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | -16.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -157.77 | |||||
| ROA % | -77.97 | |||||
| ROIC % | -393.23 | |||||
| ROC (Joel Greenblatt) % | -480.86 | |||||
| ROCE % | -114.9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.06 | |||||
| Price-to-Tangible-Book | 1.06 | |||||
| Price-to-Net-Current-Asset-Value | 5.83 | |||||
| FCF Yield % | -392.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VAXX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vaxxinity Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.45 | ||
| Beta | 0 | ||
| Volatility % | 74.01 | ||
| 14-Day RSI | 16.08 | ||
| 14-Day ATR ($) | 0.074931 | ||
| 20-Day SMA ($) | 0.46983 | ||
| 12-1 Month Momentum % | -68.14 | ||
| 52-Week Range ($) | 0.1075 - 3.1 | ||
| Shares Outstanding (Mil) | 126.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vaxxinity Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaxxinity Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vaxxinity Inc Frequently Asked Questions
What is Vaxxinity Inc(VAXX)'s stock price today?
The current price of VAXX is $0.12. The 52 week high of VAXX is $3.10 and 52 week low is $0.11.
When is next earnings date of Vaxxinity Inc(VAXX)?
The next earnings date of Vaxxinity Inc(VAXX) is 2024-05-09 Est..
Does Vaxxinity Inc(VAXX) pay dividends? If so, how much?
Vaxxinity Inc(VAXX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers